Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Bodei

Showing results (71-80 of 184) with videos related to

Pageof 19
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2022
Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of <sup>177</sup>Lu-DOTATATE in Neuroendocrine TumorsLisa Bodei, Nitya Raj, Richard K Do, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2021
The Quest for an Accurate Functional Tumor Volume with <sup>68</sup>Ga-DOTATATE PET/CTRyan P Reddy, C Ross Schmidtlein, Romina G Giancipoli, et al.
IEEE Transactions on Medical Imaging|March 4, 2026
Computed Quantitative Planar Imaging for Targeted Alpha Therapy: Model-Based Sparse Reconstruction Validated with a Novel <sup>225</sup>Ac Epoxy PhantomC Ross Schmidtlein, Jin Ren, Andrzej Krol, et al.
Mutation Research|January 30, 2002
Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131Michela Ballardin, Federica Gemignani, Lisa Bodei, et al.
Advances in Medical Sciences|December 17, 2019
The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumorsAnna Malczewska, Beata Kos-Kudła, Mark Kidd, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 26, 2025
Extravasation Frequency of [<sup>177</sup>Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients-A Single-Site AnalysisGunjan Kayal, Finn Augensen, Lisa Bodei, et al.
The Lancet. Oncology|September 5, 2020
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapyLisa Bodei, Heiko Schöder, Richard P Baum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2024
How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial DesignAna P Kiess, Joseph O'Donoghue, Carlos Uribe, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Differential Clearance of [<sup>177</sup>Lu]Lu-PSMA-617 from Metastatic Prostate Cancer Lesions and Normal Tissues creates a Window for Safe Application of DNA Repair InhibitorsJames Russell, Milan Grkovski, Joseph A O'Donoghue, et al.
Neuroendocrinology|September 27, 2019
Neuroendocrine Neoplasms of the Small Bowel and PancreasAshley Kieran Clift, Mark Kidd, Lisa Bodei, et al.
Pageof 19

Showing results (71-80 of 184) with videos related to

Sort By:
Pageof 19
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2022
Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of <sup>177</sup>Lu-DOTATATE in Neuroendocrine TumorsLisa Bodei, Nitya Raj, Richard K Do, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2021
The Quest for an Accurate Functional Tumor Volume with <sup>68</sup>Ga-DOTATATE PET/CTRyan P Reddy, C Ross Schmidtlein, Romina G Giancipoli, et al.
IEEE Transactions on Medical Imaging|March 4, 2026
Computed Quantitative Planar Imaging for Targeted Alpha Therapy: Model-Based Sparse Reconstruction Validated with a Novel <sup>225</sup>Ac Epoxy PhantomC Ross Schmidtlein, Jin Ren, Andrzej Krol, et al.
Mutation Research|January 30, 2002
Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131Michela Ballardin, Federica Gemignani, Lisa Bodei, et al.
Advances in Medical Sciences|December 17, 2019
The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumorsAnna Malczewska, Beata Kos-Kudła, Mark Kidd, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 26, 2025
Extravasation Frequency of [<sup>177</sup>Lu]Lu-DOTATATE: Insights and Implications Derived from 1,314 Cycles of Treated Patients-A Single-Site AnalysisGunjan Kayal, Finn Augensen, Lisa Bodei, et al.
The Lancet. Oncology|September 5, 2020
Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapyLisa Bodei, Heiko Schöder, Richard P Baum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2024
How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial DesignAna P Kiess, Joseph O'Donoghue, Carlos Uribe, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Differential Clearance of [<sup>177</sup>Lu]Lu-PSMA-617 from Metastatic Prostate Cancer Lesions and Normal Tissues creates a Window for Safe Application of DNA Repair InhibitorsJames Russell, Milan Grkovski, Joseph A O'Donoghue, et al.
Neuroendocrinology|September 27, 2019
Neuroendocrine Neoplasms of the Small Bowel and PancreasAshley Kieran Clift, Mark Kidd, Lisa Bodei, et al.
Pageof 19